Ferric Carboxymaltose Injection — Competitive Intelligence Brief

Ferric Carboxymaltose Injection (Ferric Carboxymaltose Injection) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Iron replacement agent. Area: Hematology.

marketed Iron replacement agent Iron metabolism pathway; transferrin receptor Hematology Small molecule

Target snapshot

Ferric Carboxymaltose Injection (Ferric Carboxymaltose Injection) — Sichuan Huiyu Pharmaceutical Co., Ltd. Ferric carboxymaltose delivers iron as a stable complex that is taken up by iron-binding proteins to replenish depleted iron stores and restore hemoglobin synthesis.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Ferric Carboxymaltose Injection TARGET	Ferric Carboxymaltose Injection	Sichuan Huiyu Pharmaceutical Co., Ltd	marketed	Iron replacement agent	Iron metabolism pathway; transferrin receptor
Iron Sucrose (Venofer)	Iron Sucrose (Venofer)	American Regent, Inc.	marketed	Intravenous iron replacement agent
Vifor and EPO	Vifor and EPO	Kunshan First People's Hospital Affiliated to Jiangsu University	marketed	Iron replacement agent and erythropoiesis-stimulating agent (ESA)	Iron (ferric ion) and erythropoietin receptor (EPOR)
Generic sodium ferric gluconate	Generic sodium ferric gluconate	University of Maryland, Baltimore	marketed	Iron replacement agent	Iron (Fe3+) delivery; hemoglobin and myoglobin synthesis
Iron isomaltoside	Iron isomaltoside	Thomas Jefferson University	marketed	Iron replacement agent	Iron (Fe3+) / transferrin receptor
ferric(III)carboxymaltose	ferric(III)carboxymaltose	Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)	marketed	Iron replacement agent	Iron metabolism / transferrin-mediated iron transport
intravenous iron carboxymaltose	intravenous iron carboxymaltose	University of Zurich	marketed	Intravenous iron replacement agent	Iron (Fe³⁺) delivery system; transferrin receptor-mediated uptake

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Iron replacement agent class)

1. University of Maryland, Baltimore · 2 drugs in this class
2. Ain Shams University · 1 drug in this class
3. American Regent, Inc. · 1 drug in this class
4. Azad Pharma AG · 1 drug in this class
5. CN NGANOU-GNINDJIO, MD, MSc · 1 drug in this class
6. China-Japan Friendship Hospital · 1 drug in this class
7. Hallym University Medical Center · 1 drug in this class
8. J. Uriach and Company · 1 drug in this class
9. JW Pharmaceutical · 1 drug in this class
10. Prince of Wales Hospital, Shatin, Hong Kong · 1 drug in this class